Antios Therapeutics is a biopharmaceutical company focused on developing innovative therapies to treat and potentially cure hepatitis B virus (HBV) and other viral diseases. The company operates in the healthcare and pharmaceutical market, primarily targeting patients suffering from chronic HBV infections. Antios Therapeutics' core product includes ATI 2173, a novel compound combined with nucleoside analogues like Tenofovir or Entecavir, designed to inhibit HBV polymerase activity and viral replication. The company is also advancing its 4th generation capsid assembly modulator (CAM) program, which aims to enhance the immune system's ability to clear the virus more effectively. Antios Therapeutics generates revenue through the development and commercialization of its proprietary drug candidates, partnering with other biopharma companies for clinical trials and potential licensing agreements. The company serves a global market, addressing a significant unmet medical need with its cutting-edge antiviral therapies.

Keywords: biopharmaceutical, hepatitis B, antiviral therapies, HBV, ATI 2173, nucleoside analogues, capsid assembly modulator, viral diseases, clinical trials, healthcare.